CONTACT
+91 80 2808 2808
info@biocon.com

Biocon’s Small Molecules API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection

  • Posted by: BIOCON

Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6%

  • Posted by: BIOCON

Biocon’s Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations

  • Posted by: BIOCON

Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia’s Highest Civilian Honour

  • Posted by: BIOCON

True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake

  • Posted by: BIOCON

Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer

  • Posted by: BIOCON

Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand

  • Posted by: BIOCON

Biocon Biologics Symposium on ‘100 years of Insulin – Delivering on Universal Access & Equitable Care’ Resonates Well with Leading KOLs at IDF Congress 2019

  • Posted by: BIOCON

Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally

  • Posted by: BIOCON

Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>